Recruiting

Testing a three-drug combination for advanced hormone-sensitive breast cancer

Plain-English translation of NCT05524584 on ClinicalTrials.gov ↗ · Source last updated October 2026 · Translation generated August 2026 · How we translate trials

Read our Breast Cancer research guide →

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a combination of three medications—, , and —given together to treat advanced breast cancer that is hormone receptor-positive and HER2-negative. These are cancers that grow in response to hormones in the body. The study wants to see if using all three medications at the same time works better than previous treatment approaches.

Many patients with this type of advanced breast cancer eventually stop responding to standard hormone-blocking treatments. This trial is exploring whether adding —a medication that works differently—to the combination of and might help patients live longer and have their cancer shrink.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced breast cancer (Stage IV) that is hormone receptor-positive and HER2-negative
you either have newly diagnosed metastatic disease OR your cancer came back more than 12 months after finishing earlier treatment
you are postmenopausal or willing to take medication to suppress ovarian function
you are 18 years or older and in generally good health
you have at least one tumor that can be measured on scans
your blood counts and organ function (liver, kidney) are adequate as measured by standard blood tests

You likely don't qualify if…

you are pregnant, breastfeeding, or unwilling to use birth control during the study
you have severe problems with your liver, kidney, or blood cell counts
you cannot swallow oral pills
you have not fully recovered from side effects of chemotherapy or radiation within the past few months

What participation looks like

You will take three medications: as a daily oral tablet, as an oral tablet twice daily, and as an injection into your muscle every two weeks for the first month, then once monthly. You will have regular clinic visits to check how well the treatment is working, including blood tests and imaging scans. The study is enrolling about 20 people and will continue until researchers determine whether this combination is effective.

AI-generated summary from trial data · Aug 11, 2026 · Not medical advice

Trial locations(1 site)

United States

Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California